Stoke Therapeutics Inc
Stoke Therapeutics Inc (STOK) Straddle
STOK straddle scan found 20 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 60.2%.
Read more
Trading a STOK straddle lets you take a pure volatility position on Stoke Therapeutics Inc without committing to a direction. Stoke Therapeutics Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate STOK straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on STOK profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Stoke Therapeutics Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the STOK straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc.
for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the STOK straddle is the cleanest expression of that view. Our scanner prices every STOK straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a STOK straddle into a catalyst or short a STOK straddle to harvest decay, the options straddle setups that matter are all in one place.
| May 21, 2027 | 40.00 | $15.95 | 245 | 20% | 60.2% | $55.95 | $24.05 | 0 |
| Feb 19, 2027 | 35.00 | $10.90 | 154 | 20% | 58.5% | $45.90 | $24.10 | 17 |
| May 21, 2027 | 35.00 | $13.23 | 245 | 20% | 58.5% | $48.23 | $21.78 | 0 |
| Feb 19, 2027 | 30.00 | $9.28 | 154 | 20% | 54.5% | $39.28 | $20.73 | 0 |
| Nov 20, 2026 | 30.00 | $6.23 | 63 | 20% | 53.4% | $36.23 | $23.78 | 34 |
| May 21, 2027 | 30.00 | $11.80 | 245 | 20% | 53.3% | $41.80 | $18.20 | 0 |
| May 21, 2027 | 25.00 | $11.33 | 245 | 20% | 45.3% | $36.33 | $13.68 | 0 |
| Dec 17, 2027 | 45.00 | $30.00 | 455 | 20% | 43.7% | $75.00 | $15.00 | 0 |
| Oct 16, 2026 | 30.00 | $5.28 | 28 | 20% | 43.4% | $35.28 | $24.73 | 1 |
| Feb 19, 2027 | 22.50 | $10.13 | 154 | 20% | 39.3% | $32.63 | $12.38 | 0 |
As of September 21, 2026
Find the right straddle before volatility moves
Track STOK straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.
Start your 14-day free trial→